<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02723110</url>
  </required_header>
  <id_info>
    <org_study_id>15/SC/0072</org_study_id>
    <nct_id>NCT02723110</nct_id>
  </id_info>
  <brief_title>Defining the Physiological Mechanisms of Risk Genes for Hyperglycaemia, Insulin Resistance and Type 2 Diabetes</brief_title>
  <acronym>DIVA - PAM</acronym>
  <official_title>Defining the Physiological Mechanisms of Risk Genes for Hyperglycaemia, Insulin Resistance and Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Exeter</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <brief_summary>
    <textblock>
      Recent genetic association studies have identified variants in the Peptidyl-Glycine
      alpha-amidating mono-oxygenase (PAM) gene that increase the risk of diabetes likely through a
      defect in beta-cell function. This has been followed up and supported by novel kinetic assays
      and cellular studies. This investigation will recall heterozygous carriers of the risk allele
      at rs78408340 and age, BMI and gender matched controls from the Oxford Biobank. The study
      will compare the incretin effect, glucagon-like peptide-1(GLP-1), insulin, glucose levels and
      PAM protein activity in individuals both with and without the risk variant. The aim of the
      study is to gain mechanistic insight into the effect of the variant on human physiology and
      diabetes pathogenesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Note: The study will utilize an adaptive study design with an interim analysis at 40
      volunteers (20 v 20) with the possibility of adding an additional 20 volunteers to the study
      (10 v 10) if the criteria for futility or clear effect are not met.

      The criteria are; stop and reject null hypothesis if t &gt; 2.490 and stop and accept null
      hypothesis if t &lt; 1.033. If the t falls between these values an additional 20 volunteers (10
      v10) will be recruited. The decision to stop or additional volunteers will be based on the
      incretin effect (primary outcome).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Calculated Incretin Effect</measure>
    <time_frame>3 months</time_frame>
    <description>Will be calculated from the amount of IV glucose required to reproduce OGTT glycaemic profile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin concentration</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose concentrations</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLP-1 (glucagon-like peptide-1) amidated and unamidated concentration</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAM enzyme activity assay</measure>
    <time_frame>3 months</time_frame>
    <description>This assay is based off the protocol in the published literature, and is based on the turnover of radio-labelled substrate to quantify the amidating ability of the PAM enzyme</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>rs78408340 heterozygous carriers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>homozygous non-risk allele carriers</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>4 Hour Frequently Sampled Oral Glucose Tolerance Test</intervention_name>
    <description>Blood glucose level(BGL) every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240</description>
    <arm_group_label>rs78408340 heterozygous carriers</arm_group_label>
    <arm_group_label>homozygous non-risk allele carriers</arm_group_label>
    <other_name>OGTT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Isoglycaemic Clamp</intervention_name>
    <description>Glucose infusion over 4 hours to reproduce OGTT glucose curve to allow measurement of incretin effect. BGL every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240</description>
    <arm_group_label>rs78408340 heterozygous carriers</arm_group_label>
    <arm_group_label>homozygous non-risk allele carriers</arm_group_label>
    <other_name>Matched clamp</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      EDTA plasma, serum, lithium heparin
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers enrolled in the Oxford Biobank
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult, age 30-65 inclusive, healthy, appropriate genotype

          -  Mental capacity to consent

        Exclusion Criteria:

          -  Demographics: &lt;30 and &gt;65 years old

          -  Medical history: Bariatric surgery, surgery on gut/ stomach; history of recent
             significant weight loss (&gt;10% of weight in last year); known cardiovascular disease

          -  Medications: Currently prescribed glucose-lowering medication, oral/IV corticosteroid
             treatment, any medication effecting gastric motility or glucose metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fredrik Karpe</last_name>
    <phone>01865 857222</phone>
    <email>fredrik.karpe@ocdem.ox.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahesh M Umapathysivam</last_name>
    <phone>01865857261</phone>
    <email>mahesh.umapathysivam@spc.ox.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OCDEM, University of Oxford</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrik Karpe</last_name>
      <phone>01865 857222</phone>
      <email>fredrik.karpe@ocdem.ox.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Mahesh M Umapathysivam</last_name>
      <email>mahesh.umapathysivam@spc.ox.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Fredrik Karpe</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mahesh Umapathysivam</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Gloyn</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark McCarthy</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrik Rorsman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2016</study_first_submitted>
  <study_first_submitted_qc>March 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2016</study_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

